---
title: "Zenas BioPharma, Inc. 1Q 2026: Revenue $16.91M, EPS ($1.46) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286244202.md"
description: "Zenas BioPharma, Inc. reported Q1 2026 revenue of $16.91M, up 69.1% from $10M a year ago, but incurred a net loss of $80.99M compared to $33.57M previously. Diluted EPS was ($1.46), worsening from ($0.8). Key developments include successful Phase 3 trial results for obexelimab, planned regulatory filings, ongoing Phase 2 trials, and pipeline expansion with new licenses. The company expects its cash runway to support operations until 2029, facilitating continued clinical advancements."
datetime: "2026-05-13T10:41:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286244202.md)
  - [en](https://longbridge.com/en/news/286244202.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286244202.md)
---

# Zenas BioPharma, Inc. 1Q 2026: Revenue $16.91M, EPS ($1.46) — 10-Q Summary

Zenas BioPharma, Inc. reported first-quarter 2026 results with revenue of $16.91M, compared with $10M in the prior-year quarter, and a net loss of ($80.99M) versus ($33.57M) a year earlier; diluted loss per share was ($1.46) compared with ($0.8) in 1Q 2025.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$16.91M

$10M

69.1%

Net income²

($80.99M)

($33.57M)

(141.2%)

Diluted EPS³

($1.46)

($0.8)

(82.5%)

_¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported as “loss per share - basic and diluted”._

**Business Highlights**

-   Clinical milestones: Phase 3 obexelimab met primary and all key secondary endpoints in IgG4‑RD; regulatory filings planned with a BLA in Q2 2026 and an EMA submission in H2 2026.
-   R&D progress: Ongoing Phase 2 trials in RMS and SLE (SunStone enrollment complete); topline SLE data expected in Q4 2026.
-   Pipeline expansion: InnoCare license adds orelabrutinib (BTK) with global MS rights plus early programs ZB021 and ZB022; Phase 3 PriMroSe for PPMS initiated.
-   Commercial preparation: Increased headcount and pre‑commercial activities to support potential launches and manufacturing scale‑up.
-   Capital position: Cash runway expected to fund operations into 2029 under current plans, supporting continued clinical advancement.

Original SEC Filing: Zenas BioPharma, Inc. \[ ZBIO \] - 10-Q - May. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ZBIO.US](https://longbridge.com/en/quote/ZBIO.US.md)
- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)

## Related News & Research

- [Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing](https://longbridge.com/en/news/286872009.md)
- [Zenas BioPharma To Present INDIGO Phase 3 Data At EULAR 2026; Wedbush Sees $45 Target](https://longbridge.com/en/news/286916856.md)
- [Zenas BioPharma Highlights Strong Q1 Progress and Financing](https://longbridge.com/en/news/286243392.md)
- [ZenaTech Advances Three ZenaDrone Defense Platforms Through Blue UAS Certification Pathway | ZENA Stock News](https://longbridge.com/en/news/286910480.md)
- [Tuesday 5/19 Insider Buying Report: ZBIO, ICFI](https://longbridge.com/en/news/286954937.md)